Equity Incentive Plans | NOTE 6: EQUITY INCENTIVE PLANS In September 2015, the Company adopted the 2015 Omnibus Incentive Plan (the “2015 Plan”). Under the 2015 Plan, the Company can issue various types of equity compensation awards such as share options, restricted shares, performance shares, restricted stock units (“RSUs”), performance units, long-term cash award and other share-based awards. Options granted under the 2015 Plan generally have a four-year vesting period and expire ten years after the date of grant. Options granted under the 2015 Plan that are cancelled or forfeited before expiration become available for future grants. RSUs granted under the 2015 Plan vest in equal installments over a three-year period. As of June 30, 2017, 9,824,964 A summary of the status of the Company’s option plans as of June 30, 2017 and changes during the period then ended is presented below: Six months ended June 30, 2017 Unaudited Number of options Weighted average exercise price Outstanding at beginning of year 11,377,354 $ 9.76 Granted 4,757,238 9.25 Exercised (639,902 ) 2.13 Forfeited and cancelled (205,370 ) 12.65 Outstanding as of June 30, 2017 15,289,320 9.88 Exercisable options 6,722,358 7.49 Vested and expected to vest 15,289,320 $ 9.88 A summary of the status of the Company’s RSUs as of June 30, 2017 and changes during the period then ended is presented below: Six months ended June 30, 2017 Unaudited Number of RSUs Weighted average grant date fair value price Unvested at beginning of year - $ - Granted 1,661,619 9.64 Vested - - Forfeited and cancelled - - Unvested as of June 30, 2017 1,661,619 $ 9.64 In September 2015, the Company adopted an employee share purchase plan (“ESPP”) to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. In the United States, the ESPP is intended to be an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code and the provisions of the ESPP will be construed in a manner consistent with the requirements of such section. The Company began its offerings under the ESPP on August 1, 2016. As of June 30, 2017, 2,328,171 ordinary shares were available to be purchased by eligible employees under the ESPP and 209,355 shares had been issued under the ESPP. The fair value of equity-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions: Six months ended June 30, Year ended December 31, 2017 2016 2016 Unaudited Audited Stock Option Plans Expected term (years) 5.5-6.25 6.25 6.25 Expected volatility 56.74%-59.15% 59.80%-61.65% 58.40%-61.70% Risk-free interest rate 1.99%-2.23% 1.23%-1.88% 1.23%-1.88% Dividend yield 0.00% 0.00% 0.00% ESPP Expected term (years) 0.50 - 0.42 Expected volatility 82.00% - 70.45% Risk-free interest rate 0.62% - 0.40% Dividend yield 0.00% - 0.00% The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and six months ended June 30, 2017 and 2016 and the year ended December 31, 2016 was: Three months ended June 30, Six months ended June 30, Year ended December 31, 2017 2016 2017 2016 2016 Unaudited Unaudited Audited Cost of revenues $ 131 $ 170 $ 274 $ 311 $ 623 Research, development and clinical trials 811 839 1,673 1,602 3,155 Sales and marketing 1,735 1,349 2,390 2,639 5,111 General and administrative 4,893 3,279 7,794 6,541 12,552 Total share-based compensation expense $ 7,570 $ 5,637 $ 12,131 $ 11,093 $ 21,441 |